20 Apr 2017
Venue: The Studio Birmingham
Date: Friday 19 May 2017
Protein turnover is crucial in maintaining cellular homeostasis and this process is largely controlled by the Ubiquitin Proteasome Pathway (UPP). The pathway consists of an enzymatic cascade that links the polypeptide cofactor Ubiquitin to specific protein targets, which mark them for degradation by the proteasome. This cascade is highly regulated and impacts virtually all cellular processes including cell cycle progression, cell proliferation, cell differentiation and apoptosis. Malfunction of the UPP has been implicated in the development of diseases such as cancer, immune disorders and neurodegeneration.
The ability to understand and manipulate the UPP is a major objective in being able to manage disease biology. While the validity of this approach was first exemplified by the proteasome inhibitor bortezomib, approved by the FDA in 2003 and used in the treatment of multiple myeloma and mantle cell lymphoma, subsequent advances in understanding the role of different components in the UPP have allowed the development of other high quality chemical probes and inhibitors.
This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly expanding field.
Craig Crews, from the Yale Centre for Molecular Discovery, will deliver the keynote talk on PROTACs: Induced Protein Degradation as a Therapeutic Strategy.
The main focus of the Yale Centre for Molecular Discovery is the application chemical approaches to the study of biological questions. Current projects explore the modes of action of biologically active natural products to investigate intracellular signalling pathways and identify novel targets for drug design and has pioneered the use of small molecules to control intracellular protein levels. Dr Crews holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He has received numerous awards and honours, including the 2013 CURE Entrepreneur of the Year Award, 2014 Ehrlich Award for Medicinal Chemistry, 2015 Yale Cancer Center Translational Research Prize, a NIH R35 Outstanding Investigator Award (2015), and the 2017 Award for Outstanding Achievement in Chemistry in Cancer Research.
Other confirmed speakers include Benedikt Kessler from the Nuffield Department of Medicine, Christopher Tinworth from GlaxoSmithKline, and Jason Brown from Ubiquigent.
SCI Members attending this meeting are able to claim CPD points.